Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 plus sorafenib in advanced hepatocellular carcinoma
NL-OMON32745Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of everolimus and sorafenib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Pharmacokinetic exposure and 1 more. Planned start Dec 2008; status: not yet recruiting.
02
Drugs
everolimussorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON32745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32745.